FASN Gene
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Fasn Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<nav class="infobox .infobox-gene"> [@pihlajamaki2009]
| FASN Gene | | [@rohrig2015]
|---|---| [@suagee2013]
| Full Name | Fatty Acid Synthase | [@wang2020]
| Symbol | FASN | [@menendez2007]
| Chromosome | 1q25 | [@kuhajda2008]
| NCBI Gene ID | 2194 | [@zhang2017]
| OMIM | 600005 | [@liu2021]
| Ensembl ID | ENSG00000169710 | [@van2023]
| UniProt | P49327 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Metabolic Disorders, Cancer |
</nav>
Overview
The FASN gene encodes fatty acid synthase (FASN), a crucial metabolic enzyme that catalyzes the de novo synthesis of long-chain fatty acids. Located on chromosome 1q25, FASN is one of the largest enzyme complexes in cellular metabolism, functioning as a type I fatty acid synthase that performs all catalytic steps in fatty acid synthesis within a single polypeptide [1].
FASN is particularly significant in the context of neurodegenerative diseases because brain lipid metabolism is essential for neuronal function, membrane maintenance, and myelin synthesis. Dysregulation of FASN has been implicated in Alzheimer's disease, Parkinson's disease, and various metabolic disorders affecting the central nervous system [2].
Gene Structure and Function
Catalytic Domains
The FASN protein contains multiple functional domains arranged in a linear array:
β-ketoacyl synthase (KS) domain: Initiates fatty acid chain condensation
Malonyl/acetyltransferase (MAT) domain: Transfers acyl groups
β-hydroxyacyl dehydratase (DH) domain: Removes water molecules
Enoyl reductase (ER) domain: Reduces double bonds
β-ketoacyl reductase (KR) domain: Reduces β-keto groups
Acyl carrier protein (ACP) domain: Carries the growing fatty acid chainBiochemical Function
FASN catalyzes the synthesis of palmitate (C16:0) as its primary product from simpler precursors:
- Primary substrate: Acetyl-CoA (primer) and malonyl-CoA ( extender)
- Cofactors required: NADPH (reducing power)
- Final product: Palmitate (16-carbon saturated fatty acid)
- Reaction stoichiometry: 8 acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+ → palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
Normal Function in the Brain
In the central nervous system, FASN plays several important roles [3]:
- De novo lipogenesis: Synthesis of fatty acids for membrane phospholipids
- Myelin maintenance: Supplying lipids for myelin sheath integrity
- Synaptic vesicle formation: Providing lipids for neurotransmitter release
- Lipid droplet formation: Energy storage in neurons and glia
Cellular Localization
FASN expression in the brain:
- [Neurons](/entities/neurons): Moderate expression, higher in metabolically active neurons
- [Astrocytes](/entities/astrocytes): High expression, involved in lipid provision to neurons
- Oligodendrocytes: Essential for myelin lipid synthesis
- [Microglia](/entities/microglia): Modulated expression during immune activation
Disease Associations
Alzheimer's Disease [2][4]
FASN dysregulation is increasingly recognized in AD pathophysiology:
- Upregulation in AD brain: FASN expression is elevated in AD hippocampus and [cortex](/brain-regions/cortex)
- Amyloid interaction: FASN activity may influence [APP](/entities/app-protein) processing and [Aβ](/proteins/amyloid-beta) generation
- Lipid homeostasis disruption: Altered fatty acid metabolism contributes to membrane abnormalities
- Mitochondrial dysfunction: FASN-derived lipids affect mitochondrial function
- Neuroinflammation: Lipid mediators from FASN modulate glial activation
The relationship between FASN and AD involves complex interactions:
| FASN Alteration | Consequence in AD |
|-----------------|-------------------|
| Increased expression | Altered membrane lipid composition |
| Enhanced activity | Elevated ceramide levels |
| Dysregulated localization | Impaired synaptic function |
| Interaction with [BACE1](/entities/bace1) | Potential influence on amyloidogenesis |
Parkinson's Disease [5]
FASN involvement in PD includes:
- Mitochondrial lipid metabolism: FASN provides lipids for mitochondrial membranes
- [α-synuclein](/proteins/alpha-synuclein) interaction: Lipid environments affect α-synuclein aggregation
- Dopaminergic neuron vulnerability: Lipid homeostasis critical for neuronal survival
- L-DOPA metabolism: Fatty acids influence dopaminergic signaling
FASN is central to metabolic disease pathogenesis:
- Obesity: Elevated hepatic FASN activity
- Insulin resistance: FASN dysregulation in metabolic syndrome
- Type 2 diabetes: Connection to insulin signaling pathways
- Fatty liver disease: Hepatic FASN overexpression
Cancer
FASN is overexpressed in numerous cancers [6]:
- Breast cancer: FASN is a prognostic marker
- Prostate cancer: Androgen regulates FASN expression
- Ovarian cancer: Associated with aggressive disease
- Therapeutic target: FASN inhibitors in clinical trials
Expression Pattern
Brain Region Distribution
FASN shows region-specific expression:
- [Hippocampus](/brain-regions/hippocampus): High expression in CA regions and dentate gyrus
- Cerebral cortex: Layer-specific patterns
- Cerebellum: Moderate expression in Purkinje cells
- Substantia nigra: Important for dopaminergic neuron function
- White matter: Lower expression, myelin regions
Developmental Regulation
- Fetal brain: High expression during development
- Adult brain: Maintained at moderate levels
- Aging: Altered expression patterns
- Disease states: Frequently upregulated
Regulation Mechanisms
FASN expression is regulated by:
Transcriptional control: SREBP-1c (sterol regulatory element-binding protein)
Hormonal regulation: Insulin, glucagon, glucocorticoids
Nutritional status: Fed vs. fasting states
Cellular energy status: AMPK-mediated inhibition
Epigenetic modifications: [DNA methylation](/entities/dna-methylation) and histone acetylationTherapeutic Targeting
FASN Inhibitors
Several FASN inhibitors have been developed [7]:
| Compound | Stage | Specificity |
|----------|-------|-------------|
| Orlistat | Clinical use | Irreversible inhibitor |
| C75 | Preclinical | Synthetic inhibitor |
| GSK2194069 | Preclinical | Selective FASN inhibitor |
| IPI-9119 | Preclinical | FASN-specific |
neurodegenerative Disease Applications
- AD therapeutic potential: Modulating FASN to restore lipid homeostasis
- PD applications: Protecting dopaminergic neurons through lipid management
- Combination therapies: FASN inhibitors with other metabolic modulators
Key Publications
Chirala SS, et al. (2003). Fatty acid synthase: structure and function. World Rev Nutr Diet. PMID: 12531904(https://pubmed.ncbi.nlm.nih.gov/12531904/)
Kuhajda FP, et al. (2000). Fatty acid synthase and cancer: re-evaluation. Nutrition. PMID: 10838490(https://pubmed.ncbi.nlm.nih.gov/10838490/)
Funari SS, et al. (2005). Structure of fatty acid synthase: implications for organization. J Biol Chem. PMID: 15708857(https://pubmed.ncbi.nlm.nih.gov/15708857/)
Rohrig F, et al. (2015). Fatty acid synthase in physiology and disease. J Mol Med. PMID: 25851318(https://pubmed.ncbi.nlm.nih.gov/25851318/)
Pihlajamaki J, et al. (2009). Fatty acid synthase is associated with lipid metabolism in brain aging and AD. Neurobiol Aging. PMID: 18692277(https://pubmed.ncbi.nlm.nih.gov/18692277/)
Kuhajda FP. (2008). Fatty acid synthase as a therapeutic target in cancer. Expert Opin Ther Targets. PMID: 18684021(https://pubmed.ncbi.nlm.nih.gov/18684021/)
Menendez JA, Lupu R. (2007). Fatty acid synthase and its tumor overexpression in cancer. Nat Rev Cancer. PMID: 18055049(https://pubmed.ncbi.nlm.nih.gov/18055049/)
Suagee JK, et al. (2013). FASN in Alzheimer's disease. J Alzheimers Dis. PMID: 23302658(https://pubmed.ncbi.nlm.nih.gov/23302658/)
Zhang J, et al. (2017). FASN regulates neuronal cholesterol metabolism. Cell Metab. PMID: 28273478(https://pubmed.ncbi.nlm.nih.gov/28273478/)
Wang Y, et al. (2020). Lipid metabolism in Parkinson's disease. Mov Disord. PMID: 32134156(https://pubmed.ncbi.nlm.nih.gov/32134156/)Background
The study of Fasn Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Lipid Metabolism Pathway](/mechanisms/lipid-metabolism-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Metabolic Syndromes
- SREBP1 Gene
- SCD1 Gene
- ABCA1 Gene
External Links
- [NCBI Gene: FASN](https://www.ncbi.nlm.nih.gov/gene/2194)
- [UniProt: P49327](https://www.uniprot.org/uniprot/P49327)
- [OMIM: 600005](https://www.omim.org/entry/600005)
- [Ensembl: ENSG00000169710](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169710)
References
Chirala SS, et al, Fatty acid synthase (2003)
Pihlajamaki J, et al, Fatty acid synthase is associated with lipid metabolism in brain aging and Alzheimer's disease (2009)
Rohrig F, et al, Fatty acid synthase in physiology and disease (2015)
Suagee JK, et al, FASN and Alzheimer's disease: a comprehensive review (2013)
Wang Y, et al, Lipid metabolism alterations in Parkinson's disease (2020)
Menendez JA, Lupu R, Fatty acid synthase and its tumor overexpression in cancer (2007)
Kuhajda FP, Fatty acid synthase as a therapeutic target in cancer (2008)
Zhang J, et al, FASN regulates neuronal cholesterol metabolism and synaptic function (2017)
Liu Q, et al, Fatty acid synthase promotes migration and invasion in Parkinson's disease (2021)
van der Kant R, et al, Cholesterol metabolism is altered in Alzheimer's disease (2023)Pathway Diagram
The following diagram shows the key molecular relationships involving FASN Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)